Perigon Wealth Management LLC Buys Shares of 5,708 Illumina, Inc. $ILMN

Key Points

• Perigon Wealth Management acquired 5,708 Illumina shares worth approximately $1.0 million during the second quarter. Institutional investors collectively own 89.42% of the company.
• Illumina reported quarterly EPS of $1.31, beating estimates by $0.08, while revenue rose 9.4% year over year to $1.16 billion. The company maintained fiscal 2026 EPS guidance of $5.30–$5.40.
• Insiders sold 1.42 million shares worth approximately $256 million over the past 90 days, including a $91.6 million sale by director Keith A. Meister. Analysts’ consensus rating remains Hold, with an average price target of $188.40.

Perigon Wealth Management LLC acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 5,708 shares of the life sciences company's stock, valued at approximately $1,004,000.

A number of other hedge funds have also bought and sold shares of the business. Elyxium Wealth LLC bought a new stake in shares of Illumina in the fourth quarter worth approximately $25,000. TD Waterhouse Canada Inc. bought a new position in Illumina during the fourth quarter valued at approximately $26,000. Laurel Wealth Advisors LLC bought a new position in Illumina during the fourth quarter valued at approximately $26,000. Elevation Wealth Partners LLC boosted its holdings in Illumina by 52.5% in the second quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company's stock worth $43,000 after purchasing an additional 84 shares during the last quarter. Finally, Activest Wealth Management boosted its holdings in Illumina by 671.9% in the fourth quarter. Activest Wealth Management now owns 247 shares of the life sciences company's stock worth $32,000 after purchasing an additional 215 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company's stock.

Insider Buying and Selling at Illumina

In related news, Director Keith A. Meister sold 457,858 shares of the firm's stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the sale, the director owned 2,372,694 shares of the company's stock, valued at $474,776,069.40. This trade represents a 16.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Scott D. Ericksen sold 1,500 shares of Illumina stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $150.10, for a total transaction of $225,150.00. Following the completion of the transaction, the chief accounting officer directly owned 14,946 shares in the company, valued at approximately $2,243,394.60. The trade was a 9.12% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 1,415,351 shares of company stock worth $255,966,311. 2.90% of the stock is currently owned by corporate insiders.

Illumina Stock Down 2.5%

Shares of NASDAQ ILMN opened at $188.29 on Wednesday. Illumina, Inc. has a 1 year low of $88.00 and a 1 year high of $207.00. The firm has a 50-day simple moving average of $185.05 and a two-hundred day simple moving average of $151.10. The company has a market cap of $28.43 billion, a P/E ratio of 35.13, a PEG ratio of 2.69 and a beta of 1.44. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.13 billion. During the same period in the previous year, the company earned $1.19 EPS. The firm's quarterly revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Research analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current year.

Analyst Upgrades and Downgrades

ILMN has been the topic of a number of recent research reports. TD Cowen increased their target price on Illumina from $192.00 to $210.00 and gave the company a "hold" rating in a report on Friday, July 31st. Citigroup increased their target price on shares of Illumina from $95.00 to $113.00 and gave the stock a "sell" rating in a report on Monday, August 3rd. Leerink Partners increased their target price on Illumina from $175.00 to $210.00 and gave the stock an "outperform" rating in a research report on Friday, July 17th. Royal Bank Of Canada boosted their price target on Illumina from $170.00 to $230.00 and gave the stock an "outperform" rating in a report on Friday, July 31st. Finally, Weiss Ratings upgraded Illumina from a "hold (c-)" rating to a "hold (c)" rating in a research note on Wednesday, June 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, Illumina presently has an average rating of "Hold" and a consensus target price of $188.40.

About Illumina

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source